BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GC101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GC101\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05142475-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:GC101: Phase 1 readout est. (NCT05142475)
DESCRIPTION:GC101\, phase 1.\nStudy: A Study of GC101 TIL in Advanced Breas
 t Cancer (10hospital)\nEstimated primary completion: 20 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05142475
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04943913-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:GC101: Phase 1 readout est. (NCT04943913)
DESCRIPTION:GC101\, phase 1.\nStudy: Study of GC101 TIL in Brain Glioma (So
 ochow2)\nEstimated primary completion: 30 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/gc101#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04943913
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473961-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:GC101: Phase 1 readout est. (NCT06473961)
DESCRIPTION:GC101\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 b Study of GC101 in NSCLC\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473961
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560111-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:GC101: Phase 2 readout est. (NCT07560111)
DESCRIPTION:GC101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Study of GC101 in NSCLC\nEstimated primary completion: 1 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07560111
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294872-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:GC101: Phase 1 readout est. (NCT07294872)
DESCRIPTION:GC101\, phase 1.\nStudy: A Study of TIL in Advanced Solid Tumor
 s (CZ)\nEstimated primary completion: 20 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/gc101#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07294872
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04967833-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:GC101: Phase 1 readout est. (NCT04967833)
DESCRIPTION:GC101\, phase 1.\nStudy: A Study of GC101 TIL in Advanced Solid
  Tumors (TR)\nEstimated primary completion: 22 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04967833
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04960072-8738@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:GC101: Phase 1 readout est. (NCT04960072)
DESCRIPTION:GC101\, phase 1.\nStudy: A Study of GC101 TIL in r/r Gastrointe
 stinal Tumors (10hospital)\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04960072
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
